Be a Smart Investor
Monday, August 22, 2016
Pfizer-Medivation cash deal is hard to justify: Analyst
Pfizer investors should be concerned about the high premium, while Medivation investors should celebrate, says RBC Capital Markets' Simos Simeonidis.
from Mergers and Acquisitions http://ift.tt/2bd36it
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment